Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...

Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System Dallas, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Roo System: a...